Drug Trial Radar · NCT03976323
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,003
Actual
Start
Jun 28, 2019
Primary completion
Feb 7, 2024
Study completion Jan 30, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).
Conditions
- Carcinoma, Nonsquamous Non-small-cell Lung
Interventions
PembrolizumabBiological
IV infusion
PemetrexedDrug
IV infusion
CarboplatinDrug
IV infusion
CisplatinDrug
IV infusion
OlaparibDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to ~31 months
- Overall Survival (OS)Time frame: Up to ~51 months
Locations
178 sites in 20 countries. Site status is shown where the registry gives one.
Alabama Oncology Bruno Cancer Center ( Site 0001)
Birmingham, Alabama
Northwest Alabama Cancer Center, PC ( Site 0002)
Muscle Shoals, Alabama
Disney Family Cancer Center ( Site 0005)
Burbank, California
Boca Raton Regional Hospital ( Site 0018)
Boca Raton, Florida
Mid-Florida Cancer Centers ( Site 0022)
Orange City, Florida
Moffitt Cancer Center ( Site 0024)
Tampa, Florida
Columbus Regional Research Institute ( Site 0098)
Columbus, Georgia
Mount Sinai Hospital Medical Center ( Site 0032)
Chicago, Illinois
Oncology of Northshore ( Site 0033)
Rolling Meadows, Illinois
Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0036)
Merrillville, Indiana
Medstar Good Samaritan Hospital ( Site 0040)
Baltimore, Maryland
Barbara Ann Karmanos Cancer Institute ( Site 0041)
Detroit, Michigan
Hattiesburg Clinic ( Site 0045)
Hattiesburg, Mississippi
Frontier Oncology ( Site 0080)
Billings, Montana
Bozeman Health Deaconness Cancer Center ( Site 0046)
Bozeman, Montana
Waverly Hematology Oncology ( Site 0081)
Cary, North Carolina
Thompson Cancer Survival Center ( Site 2812)
Knoxville, Tennessee
University of Tennessee Medical Center Knoxville ( Site 0060)
Knoxville, Tennessee
Renovatio Clinical ( Site 0062)
The Woodlands, Texas
Cancer Care Northwest ( Site 0071)
Spokane Valley, Washington
Clínica Universitaria Reina Fabiola ( Site 0505)
Córdoba, Argentina
Sanatorio Privado San Geronimo S.R.L ( Site 0510)
Santa Fe, Argentina
Hospital Italiano Regional del Sur ( Site 0509)
Bahía Blanca, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0511)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Britanico de Buenos Aires ( Site 0500)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto Medico Rio Cuarto ( Site 0501)
Río Cuarto, Córdoba Province, Argentina
Centro Oncológico de Rosario ( Site 0507)
Rosario, Santa Fe Province, Argentina
Centro Medico San Roque ( Site 0506)
San Miguel de Tucumán, Tucumán Province, Argentina
Liverpool Hospital ( Site 1201)
Liverpool, New South Wales, Australia
Southern Medical Day Care Centre ( Site 1200)
Wollongong, New South Wales, Australia
Townsville General Hospital ( Site 1202)
Townsville, Queensland, Australia
Monash Cancer Centre ( Site 1205)
Clayton, Victoria, Australia
Krankenhaus Nord - Klinik Floridsdorf ( Site 1300)
Vienna, Austria
Social Medical Center - Otto Wagner Hospital ( Site 1301)
Vienna, State of Vienna, Austria
Innsbruck LKH ( Site 1302)
Innsbruck, Tyrol, Austria
Ordensklinikum Linz GmbH Elisabethinen ( Site 1307)
Linz, Upper Austria, Austria
Klinikum Wels-Grieskirchen ( Site 1304)
Wels, Upper Austria, Austria
Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0203)
Rio de Janeiro, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0200)
São Paulo, Brazil
BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0214)
São Paulo, Brazil
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.